Attorney Docket No. 25627-501

Express Mail Label No.: EV 312713611 US

Date of Deposit: October 15, 2003

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ZICANT:

Li, et al.

SERIAL NUMBER:

10/622,854

EXAMINER: Not Yet Assigned

FILING DATE:

July 17, 2003

ART UNIT:

Not Yet Assigned

For:

ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF

## **MAIL STOP IDS**

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

### TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Copies of Cited References A1-A3 and C1-C9; and
- 4. Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25627-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.


Address all written correspondence to

Customer No.: 30623 Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: October 15, 2003

TRA 1842226v1

Express Mail Label No.: EV 312713611 US



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Li, et al.

SERIAL NUMBER:

10/622,854

EXAMINER:

Not Yet Assigned

FILING DATE:

July 17, 2003

ART UNIT:

Not Yet Assigned

For:

ACTIVATED CHECKPOINT THERAPY AND METHODS OF USE THEREOF

## MAIL STOP IDS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before receipt of a first Office Action on the merits. Accordingly, no fee is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT:

Li, et al.

U.S.S.N.:

10/622,854

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25627-501.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623 Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: October 15, 2003

TRA 1842222v1

Express Mail No.: EV 312713611 US Date of Deposit: October 15, 2003

Please type a plus sign (+) in this box +

Under the Paperwork R

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/622,854	
Filing Date	07/17/2003	
First Named Inventor	Li	
Group Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	25627-501	

(use as many sheets as necessary)

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	6,458,974	10/01/02	Jiang and Hogeland			09/19/01

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A2	2002/0169135	11/14/02	Pardee, et al.			11/07/01
	A3	2003/0091639	05/15/03	Jiang and Reddy			10/10/01

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C1	Boorstein, et al. (1984). Biochem. Biophys. Res. Commun. 118(3): 828-834.			
	C2	Boothman, et al. (1989). Cancer Res. 49: 605-612.			
	C3	Goncalves de Lima, et al. (1962). Rev. Inst. Antibiot. Univ. Recife. 4: 3-17.			
	C4	Hooker (1936). J. Am. Chem. Soc. <u>58</u> : 1181-1190.			
	C5	Li (1999). Mol. Med. <u>5</u> : 232-239.			
	C6	Li, et al. (1993). J. Biol. Chem. 268(30): 22463-8.			
	C7	Li, et al. (1993). Proc. Natl. Acad. Sci. USA 90: 1839-1842.			
	C8	Li, et al. (1995). Cancer Res. <u>55</u> : 3712-3715.			
	C9	Li, et al. (1999). Proc. Natl. Acad. Sci. USA 96(23): 13369-74.			

* a copy of th	nis reference is not pro	vided as it was previously cited by or submitted to the office in a prior application,
Serial No.: _	, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120
(continuation	, continuation-in-part,	and divisional applications).

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.